BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38503521)

  • 21. [Detection of del(17p13) among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance].
    Lu X; Chen L; Shi Q; Qiu H; Li J; Guo R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1087-1091. PubMed ID: 32924107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Significance of
    Ye F; Wang T; Liu A; Li Y; Li N; Wang H; Chen W
    Turk J Haematol; 2021 Dec; 38(4):246-253. PubMed ID: 33938208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
    Guo R; Shen XX; Xia Y; Jin YY; Li JY; Chen LJ; Qiu HR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):768-773. PubMed ID: 38926965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
    Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
    Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between Clinical Factors and Prognosis in Newly Diagnosed Multiple Myeloma.
    Zhao XQ; Zhao SY; Chen WX; Liu XW; Yan HX; Lou YJ
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):601-605. PubMed ID: 32703344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
    Perroud C; Thurian D; Andres M; Künzi A; Wiedemann G; Zeerleder S; Bacher U; Pabst T; Banz Y; Porret N; Rebmann E
    Hematol Oncol; 2023 Dec; 41(5):912-921. PubMed ID: 37452600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and Prognostic Implications of FGFR3
    Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
    Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
    Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].
    Zhang FJ; Zhou X; Liu SZ; Liu SJ; Liu Y; Zhuang JL
    Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):673-680. PubMed ID: 37263950
    [No Abstract]   [Full Text] [Related]  

  • 33. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
    Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
    Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
    Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
    D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
    J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.
    Zhang L; Chen S; Huang M; Wang W; Liang Y; Wang Y
    Ann Hematol; 2023 Jan; 102(1):125-132. PubMed ID: 36441260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.